INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Under the Paperwork Reduction Act of 1995, no persons are required

Application Number		10775699		
Filing Date		2004-02-10		
First Named Inventor	David	Bebbington		
Art Unit		1624		
Examiner Name	Tamt	hom Ngo Truong		
Attorney Docket Number		VPI/00-130-07 DIV US		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6558657	B1	2003-05-06	Mandeville, III et al.	
	2	6495582	B1	2002-12-17	Hale et al.	
	3	6528509	B1	2003-03-04	Hale et al.	
If you wis	h to a	dd additional U.S. Pater	t citatio	n information pl	ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030078166	A1	2003-04-24	Davies et al.	
	2	20050004110	A1	2005-01-06	Bebbington et al.	
	3	20030073687	A1	2003-04-17	Bebbington et al.	

	Application Number		10775699
	Filing Date		2004-02-10
INFORMATION DISCLOSURE	First Named Inventor	First Named Inventor David Bebbington	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1624
(NOTION SUBMISSION UNDER STOCK 1.33)	Examiner Name	Tamt	nom Ngo Truong
	Attorney Docket Numb	er	VPI/00-130-07 DIV US

4	20030064981	A1	2003-04-03	Kneglel et al.	
5	20030055044	A1	2003-03-20	Davies et al.	
6	20030083327	A1	2003-05-01	Davies et al.	
7	20040097501	A1	2004-05-20	Bebbington et al.	
8	20030078275	A1	2003-04-24	Bebbington et al.	
9	20030055068	A1	2003-03-20	Bebbington et al.	
10	20030036543	A1	2003-02-20	Bebbington et al.	
11	20040002496	A1	2004-01-01	Bebbington et al.	
12	20030225073	A1	2003-12-04	Bebbington et al.	
13	20040009974	A1	2004-01-15	Bebbington et al.	
14	20030199526	A1	2003-10-23	Choquette et al.	

15	20030092714	A1	2003-05-15	Cao et al.	
16	20040229875	A1	2004-11-18	Cao et al.	
17	20030096816	A1	2003-05-22	Cao et al.	
18	20040023963	A1	2004-02-05	Cao et al.	
19	20030207873	A1	2003-11-06	Harrington et al.	
20	20030096813	A1	2003-05-22	Cao et al.	
21	20030144309	A1	2003-07-31	Choon-Moon	
22	20040009996	A1	2004-01-15	Moon et al.	
23	20030171389	A1	2003-09-11	Bernis et al.	
24	20040029857	A1	2004-02-12	Hale et al.	
25	20050234059	A1	2005-10-20	Hale et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10775699			
Filing Date		2004-02-10			
First Named Inventor	David	David Bebbington			
Art Unit		1624			
Examiner Name	Tamthom Ngo Truong				
Attorney Docket Numb	er	VPI/00-130-07 DIV US			

26	20040097531	A1	2004-05-20	Ledeboer et al.		
27	20030022885	A1	2003-01-30	Bebbington et al.		
28	20030004161	A1	2003-01-02	Bebbington et al.		

If you wish to add additional U.S. Published Application citation information please click the Add button FOREIGN PATENT DOCUMENTS Remove

FOREIGN PATENT DOCUMENTS									
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т	
	1	0019811	EP	A1	1980-12-10	Ciba-Geigy AG			
	2	2052487	GB	A	1981-01-28	Ciba-Geigy AG			
	3	06-65237	JP	A	2007-10-25	Nissan Chem. Ind., Ltd.		×	
	4	10-130150	JP	A	1998-05-19	Dainippon Pharmaceutical Co., Ltd.		×	
	5	2458965	DE	A1	1976-06-16	Bayer AG			
	6	2000-026421	JP	A	2000-01-25	Kumiai Chem Ind. Co. Ltd.		×	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10775699		
	Filing Date		2004-02-10		
First Named Inventor David			Bebbington		
	Art Unit		1624		
	Examiner Name	Tamt	hom Ngo Truong		
	Attorney Docket Numb	or	VPIM0.130.07 DIV US		

	7	9918781	wo	A1	1999-04-22	Cytovia, Inc.			
	8	9965897	wo	A1	1999-12-23	Chiron Corporation			
	9	0218346	wo	A1	2002-03-07	Pfizer Products Inc.			
If you wisl	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button	Add		
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	Alonso, M. et al., "GSK-	Alonso, M. et al., "GSK-3 Inhibitors: Discoveries and Develoments", Current Medicinal Chemistry, 11, 755-763 (2004).						
	2	Anonymous, "Vertex Inhibitors of Aurora-2, glycogen synthase kinase-3 and Src Kinase", Expert Opn. Ther. Patents, 14(3): 459-443 (2004).							
	3	Barg, G.U. et al., "Triactines and Related Products. Part 28' Conversion of 3-Ary4-(2-cyanopheny1) triazenes into 3- Ary4qu i nazol i n-4(3H)-ones with Formamide* J. Chem. Soc. Perkin Trans. I, 3765-2766 (1884).							
	4	Bischoff, J.R., et al., "A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers", The EMBO Journal, 17(11): 3052–3065 (1998).							
	5	Bischoff, J.R., et al., "The Aurocafipthy kinase family: regulators of chromosome segregation and cytotinesis", CELL BIOLOGY, 9, 454-459 (1999).							
	6	Brunsvick, D.J. et al., "Cyclic Amdrines. Part XXII. Novel Isomerism of Disubstituted Tricycoccunazolines and Molecular Covertations in Carconogenesis", J. Chem. SOC. (C). 2841-2847 (1970).							

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Art Unit
Examiner N
Attorney Do

Application Number		10775699			
Filing Date		2004-02-10			
First Named Inventor	David Bebbington				
Art Unit		1624			
Examiner Name	Tamthom Ngo Truong				
Attorney Docket Numb	er	VPI/00-130-07 DIV US			

7	Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th ed., Vol. 1: Principles and Practice, 975-977 (1995).	
8	Cohen, P. et al., "The renaissance of GSK3," Nat. Rev. Mol. Biol., 2, 769-776 (2001).	
9	Eldar-Finkelman, H. et al., "Challenges and opportunities with glycogen synthese kinase-3 inhibitors for insulin resistance and Type 2 diabeties treatment," Expert Opinion on Investigational Drugs, 12(9): 1511-1519 (2003).	
10	Harrington, E.A. et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nat. Med., 10(3): 262-267 (2004).	
11	Heutink, P., "Untangling tau-related dementia", Hum. Mol. Genet., 9(6): 979-986 (2000).	
12	Nigg, E.A., "Mitotic Kinases as Regulators of Cell Division and its Checkpoints," Nat. Rev. Mol. Cell Biol., 2; 21-32 (2001).	
13	Traxier, P. et al., "Use of a Pharmscophore Model for the Design of EGF-R Tyrosine Knase inhibitors: 4- (Phenylamino)gyrazoic(3,4-djpyrfmdines," J. Med. Chem., 40, 3601-3616 (1997).	
14	CAPLUS listing Accession No. 1994-292136, Nakajima, Y. et al., "Pyrazoles agricultural and horticultural bactendides," JP 06065237 (1994).	
15	DATABASE CA "Online" Chemical Abstract Service, Columbus, OH, US, Kelssev, V.I. et al., "Synthesis of amino derivatives of 1.3.5-finizane containing 1.3.4-finiadiazole fingments," Database Accession No. 1996 59514 XP002224653 data-set. at LVTESTIVA YYSSHIRCH UCHEBNOH ZAVEDENII, KHIMIYA I KHIMICHESKAYA TEKHNOLOGIYA, 40(5): 27-32 (1997).	
16	Chaimers, D.T. et al., "Corticotrophin-releasing factor receptors: from molecular biology to drug design," TiPS, 17, 759-776 (2001).	
17	Km et al., "GSK3, a master switch regulating cell-fate specification and lumorigenesis," Current Opinion in Genetics & Development, 10:308-514 (2000).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David	Bebbington
Art Unit		1624
Examiner Name Tar		nom Ngo Truong
Attorney Docket Number		VPI/00-130-07 DIV US

18	Lyrer, P., Schweiz, Med. Woohen Schr., 124(45); 2005-2012 (1994).	
19	Douglas, et al., "Introduction to Viral Disease, Cecil Textbook of Medicine, 20th Edition, Vol. 2, 1739-1749 (1996).	
20	Banker, G.S. et al., "Modern Pharmaceutics", 451 & 596, 3rd ed., Marcel Dekker, New York (1996).	
21	Lovestone, S. et al., "Atzhermer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells", Curr. Biol., 4(12), 1077-86 (1994).	
22	Ivashchenko A. V. et al., "Synethsis and Study of Heteroaromatic Ligands Containing a Pyrimidine Ring", Khim. Geterosaki: Soedin., (12), 1673-7, (1980) (in English).	
23	Browniess, J. et al., "Tau phosphorylation in transgeno mice expressing glycogen synthase kinase-3beta transgenes", Neuroreport, 8(15), 3251-5 (1997).	
24	Bisgi, G. et al., "Synthesis of 4,6 Disubstituted and 4.5,6-Trisubstituted-2-Phenyl-pyrmidines and Ther Affinity Towards A1 Adenosine Receptors", Farmaco., 52(1), 61-65 (1997).	
25	All, N.M. et al, "Palladum-Catalyzed Cross Coupling Reactions of Arythoronic Acids with Ph-Deficient Heteroaryl Chlorides" Tetrahedron, 48 (37), 8117-8126 (1992).	
26	Zhang, Z. et al., "Destabilization of & caterin by mutations in presentin-1 potentiates neuronal apoptosis", Nature, 395, 698-702 (1999)	
27	Takashima, K. et al., "Tau Prolein Kinase I is Essential for Amyloid 8-Prolein-Induced Neurolaxicity", PNAS 90, 7789-7793 (1993).	
28	Pe, J et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Bran", J. Neuropathol. Exp., 56, 70-78 (1997).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David Bebbington	
Art Unit		1624
Examiner Name Tam		hom Ngo Truong
Attorney Docket Number		VPI/00-130-07 DIV US

29	IUPAC Compendium of Chemical Terminology on a definition of "alighatic compounds" found from http://www. chemisoc.org/chemityfes/goldbook/index.htm (last visited on November 16, 2007).	
30	Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure found from http:// www.chem.gmul.so.uk/upac/class/lindex.html (last visited on November 18, 2007).	
31	Nomenclature found from http://www.cem.msu.edu/-reusch/VirtualText/homen1.htm (last visited on November 18, 2007).	
32	Bokemeyer, D. et al., "Multiple intracellular MAP kinase signaling cascades", Kidney Int., 49, 1187-1198 (1996).	
33	Anderson, N.G. et al., "Multiple intracellular MAP kinase signaling cascades", Nature, 343, 651-653 (1990).	
34	Crews, C.M. et al., "The Primary Structure of MEK, a Protein Kinase That Phosphorylates the ERK Gene Product", Science, 258, 478-480 (1992).	
35	Bjorbaek, C. et al, 'Divergent Functional Roles for p90rsk Klinase Domains', J. Biol. Chem., 270(32), 18948-18552 (1995).	
36	Rouse, J. et al., A Novel Kinase Cascade Tinggered by Stress and Heat Shock That Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, 78, 1027-1037 (1994).	
37	Raingeaud, J. et al., MMK3- and MMK6-Regulated Gene Expression is Mediated by p38 Mitogen-Activated Protein Knase Signal Transduction Pathway*, Mol. Cell. Biol., 16, 1247-1255 (1996).	
38	Chen, R.H. et al., 'Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase', Proc. Natl. Acad. Sci. USA, 90, 10952-10956 (1993).	
39	Moodle, S.A. et al., "Complexes of Ras-GTP with Rat-1 and Milogen-Activated Protein Kinase Kinase", Science, 260 (5114), 1658-1661 (1903).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David	Bebbington
Art Unit		1624
Examiner Name	Tamt	nom Ngo Truong
Attorney Docket Number		VPI/00-130-07 DIV US

40	Frey, R.S. et al., "Involvement of Extracellular Sygnal-regulated Knases 2 and Stress-schoolsed Protein Kinssoliun N- Terminal Knase. Advision by Transforming Growth Factor & In the Negative Growth Central of Breast Canc
41	Sivaraman, V.S., et al., "Hyperexpression of Mitogen-activated Protein Kinase in Hurran Breast Cancer", J. Clin. Invest., 99(7), 1478-1433 (1997).
42	Whelchel, A. et al., "Inhibition of ERK Activation Attenuates Endothelin-simulated Airway Smooth Muscle Cell Proliferation", Am. J. Respir. Cell Mol. Biol., 16, 589-596 (1997).
43	Vusn, Z.O. et al., "Frequent activation of AKT2 and induction of apoptoses by whibition of phosphomostitide-3-OH kinese/Akt pathway in human oversen cencer", Choopene, 19, 2324-2330 (2000).
44	Namikawa, T. J., et al., "AkliProtein Kinase B Prevents Injury-Induced Motoneuron Death and Accelerates Axonal Regeneration", J. of Neuroscience, 20(8), 2875-2986 (2000).
45	Moline, T.J. et al., "Protound block in thymocyte development in mice lacking p56isk", Nature, 357, 161-164 (1992).
46	Kmura, M. et al., "Cell Cycle-dependent Expression and Centrosome Localization of a Third Human Autoral/pri- related Protein Kinase, AIRS", J. Biol. Chem., 274(11), 13766-13771 (1997).
If you wish to ac	d additional non-patent literature document citation information please click the Add button Add
	EXAMINER SIGNATURE
Examiner Signa	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if

EFS Web 2.0.1

English language translation is attached.